Clinical Trials in Cleveland

Showing 8341-8360 of 19,775 trials

Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

NCT02579811

Axitinib is a drug which is approved by the FDA for patients with advanced kidney cancer who have already received some treatment. It works by reducing blood flow to a tumor. Axitinib is normally give at 5mg twice per day and sometimes this dose is increased if patients tolerate it. The purpose of this study is to figure out a different way to decide which dose of axitinib each patient should receive based on the side effects they experience.

Metastatic Renal Cell Cancer

Case Comprehensive Cancer Center40 participantsStarted Dec 2015

Duarte, California, United States • Cleveland, Ohio, United States • Columbus, Ohio, United States +1 more locations

COMPLETEDPhase 2< 1 mile

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

NCT00049530

RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have stage IV melanoma.

Melanoma (Skin)

Eastern Cooperative Oncology Group32 participantsStarted Jan 2004

Birmingham, Alabama, United States • Lakeland, Florida, United States • Bloomington, Illinois, United States +29 more locations

Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Find Trials by Condition in Cleveland

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer

Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

Dissemination and Implementation of Stroke Prevention Looking at the Care Environment

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

MP1032 Treatment in Patients With Moderate to Severe COVID-19